SCHEMBL25166285

SCHEMBL25166285

CC(C)(C)OC(=O)Nc1cc(OCCCN2CCCC2)c2c(c1)OCO2

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.46
BACE1 P56817 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.40
EPHX2 P34913 1/20 0.40
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
HRH3 Q9Y5N1 3/20 0.39
KCNH2 Q12809 1/20 0.39
SRC P12931 2/20 0.38
CD274 Q9NZQ7 1/20 0.38
BCHE P06276 2/20 0.37
KDR P35968 1/20 0.37
CSK P41240 1/20 0.37
EPHB4 P54760 1/20 0.37
TEK Q02763 1/20 0.37
NR1I3 Q14994 1/20 0.37
MET P08581 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30330061 0.92 ACHE (0.46) ACHEBACE1L3MBTL1EPHX2KDM4E
SCHEMBL31108052 0.92 ACHE (0.46) ACHEBACE1L3MBTL1EPHX2KDM4E
SCHEMBL30330289 0.86 NPC1 (0.39) L3MBTL1KDM4EALDH1A1TSHRHTT
SCHEMBL25166567 0.83 ACHE (0.45) ACHEBACE1L3MBTL1EPHX2KDM4E
SCHEMBL25166072 0.81 ACHE (0.43) ACHEBACE1L3MBTL1KDM4EALDH1A1
SCHEMBL25166450 0.78 ACHE (0.50) ACHEBACE1L3MBTL1KDM4EALDH1A1
SCHEMBL31107973 0.78 ACHE (0.50) ACHEBACE1L3MBTL1KDM4EALDH1A1
SCHEMBL31108023 0.77 MEN1 (0.46) KDM4EALDH1A1TSHRHTT
SCHEMBL25166306 0.77 MEN1 (0.46) KDM4EALDH1A1TSHRHTT
SCHEMBL25166435 0.77 ACHE (0.44) ACHEBACE1L3MBTL1EPHX2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. 2024-11-07 US disclosed
CN-118647610-A Novel modulators of EHMT1 and EHMT2 and therapeutic uses thereof 探戈医药股份有限公司 2024-09-13 CN disclosed
EP-4416143-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-08-21 EP disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed
WO-2023064586-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368139-A1 NOVEL MODULATORS OF EHMT1 AND EHMT2 AND THERAPEUTIC USE THEREOF EHMT1, EHMT2, SHMT1 ACHE 4395/4885BACE1 4079/4885L3MBTL1 976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.